Q
QuantAbundanceAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

30,452 signal articles · 144 in last 24h · 154,112 total before filter · latest 46m ago
144last 24h
877last 7d
147● bullish (7d)
98● bearish (7d)
214publishers
AllMacro210Earnings108M&A125Regulatory22Product21Analyst17
✕ clear all filtersticker: GILDsentiment: bullishSentiment:bullishneutralbearishshow all (incl. clickbait)
BofA biotech scorecard: Two buys and odd one out
TheStreet41d agobullish
BofA biotech scorecard: Two buys and odd one out

Picture three students turning in exams on the same day, covering the same material. Two walk away with high marks. The third has been raising his grades all semester, yet still gets flagged for summer school. That is roughly the dynamic inside the BofA research note on biotech I received on the ...

Gilead (GILD) Wins FDA Approval for Trodelvy in TNBC
Insider Monkey89d agobullish
Gilead (GILD) Wins FDA Approval for Trodelvy in TNBC

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 12 Most Profitable S&P 500 Stocks to Invest In. On June 25, 2026, the Food and Drug Administration approved Trodelvy from Gilead Sciences, Inc. (NASDAQ:GILD) for two indications in adults with triple-negative breast cancer. The first approval covers sacituzumab govitecan-hziy as a single agent for the first-line […]